Clarendon House
2 Church Street
Hamilton HM 11
Bermuda
https://www.kiniksa.com
Sector(s):Â Healthcare
Industry:Â Biotechnology
Full Time Employees:Â 215
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Sanj K. Patel | CEO & Chairman | 1.43M | N/A | 1970 |
Mr. Mark Ragosa C.F.A. | Sr. VP & CFO | N/A | N/A | 1975 |
Mr. Eben Tessari | Sr. VP & COO | N/A | N/A | 1982 |
Mr. Michael R. Megna CPA | Chief Accounting Officer & Group VP of Fin. | N/A | N/A | 1971 |
Ms. Mei Jang | Sr. VP of Technical Operations | N/A | N/A | N/A |
Rachel Frank | Associate Director of Investor Relations | N/A | N/A | N/A |
Mr. Chad Morin | VP, Chief Compliance Officer & Data Protection Officer | N/A | N/A | N/A |
Ms. Madelyn Zeylikman | VP, Gen. Counsel & Sec. | N/A | N/A | N/A |
Ms. Melissa Manno | SVP & Chief HR Officer | N/A | N/A | N/A |
Dr. John F. Paolini | Sr. VP & Chief Medical Officer | N/A | N/A | 1965 |
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Kiniksa Pharmaceuticals, Ltd.’s ISS Governance QualityScore as of May 1, 2022 is 10. The pillar scores are Audit: 4; Board: 9; Shareholder Rights: 10; Compensation: 8.